Univ.-Prof. Dr. med. Christoph Thiemermann

Senior Medical Advisor Translational Research

Chris(toph) Thiemermann is Professor of Pharmacology and Centre Lead for Translational Medicine & Therapeutics at the William Harvey Research Institute (WHRI), Queen Mary University of London (QMUL) and Deputy Director of the Centre for Diabetic Kidney Disease at the Royal London Hospital, Bart’s Health NHS Trust. He graduated with honours in Medicine (1986), obtained his MD in Medicine (1987, summa cum laude) from the University in Cologne in Germany (awarded University Prize 1987 for ’Best Doctorate Degree of all Faculties of the University of Cologne’) and received consecutive Fellowships from the Deutsche Forschungsgemeinschaft (DFG) and the Thyssen Foundation (Germany). He joined the WHRI in July 1987, where he obtained a PhD in Pharmacology under the supervision of The Nobel Laureate Sir John Vane in 1991. Thiemermann is a Scientist/Clinician with a strong research track record in cardiovascular disease (acute medicine, renal disease, shock) with a specific expertise in target discovery, pharmacology and translational medicine. Since 2007, he is Centre Lead for Translational Medicine at the WHRI/Barts NHS Trust and (since 2015) Deputy Director of the Centre for Diabetic Kidney Disease at Bart’s Health NHS Trust. Recent successes have been phase II RCTs evaluating the effects of pentoxiphylline in patients with chronic kidney disease (on dialysis) and the repositioning of the antimalarial drug artesunate for patients with severe haemorrhage and organ failure (ongoing).His research was recognised by Awards of the British Pharmacological Society (1994), the Surgical Infection Society Europe (1999) and the Menarini-Award for CV Research (2001). Over the years, Thiemermann’s research has been generously supported by the British Heart Foundation (Senior Fellow from 1996 to 2001), the European Union, the Medical Research Council, Kidney Research UK and William Harvey Research Foundation, Barts and the London Charity (BLC) and the National Institute for Health Research (NIHR).
As an Educator, he has supervised more than 25 PhD-students, many of which have become leaders in theirs chosen fields of endeavour (medicine/research/business/regulatory affairs). Together with Mauro Perretti, he has developed the Module
Business & Pharmacology for the BSc in Pharmacology of QMUL, and serves as a mentor for QMUL, the Academy of Sciences and the NIHR.

As a Scientist, he has published more than 420 scientific articles in peer-reviewed scientific journals, which have been cited more than 30,000-times (h-index:91, Google Open Scholar). He is a Fellow of the Academy of Medical Sciences of the United Kingdom (since 2003), where he serves on the Nomination Committee (Pharmacology, Physiology & Neuroscience), a Member of the Helix Group of the Academy (since 2017), a Fellow of the British Pharmacological Society (since 2005), a Foreign Life Peer Member of the Academy of Sciences of Portugal (Lisboa) (since 2003), a Member/Deputy Chair and Chair of the Fellowships Committee of the NIHR (2008-2018), Member of the Training Implementation Group of the NIHR (since 2017), Past-President of the European Shock Society (presidency 2008-2011), Member of the Executive Council of the World Federation of Shock Societies (since 2008), Senior Associate Editor (Europe) of the Journal Shock (2003-17) and an Associate Editor of Frontiers in Immunology (Inflammation) (since 2017). Thiemermann has significant commercial and drug development experience and
(since 1995) is a Director, and since 2003 the CEO of William Harvey Research Limited (www.williamharvey.co.uk). Since 2003, this not-for-profit company has generated in excess of £ 10 Million in research funds for the William Harvey Research Institute (WHRI), and donated more than £ 1 Million to its charity, the William Harvey Research Foundation (WHRF). Thiemermann has been a key driver overseeing the development of the WHR brand since he became a director of the trading company in 1995. Before this, he was the founding managing director of European Research
management (ERM) Limited (est. 1991).
For his contributions as Scientist/Educator and Business Leader, Thiemermann is named in WHO’s WHO in Science and Engineering (since 2003), WHO’s WHO in the World (since 2004) and in 2018 has been awarded the Albert Nelson Marquis Lifetime Achievement Award by the WHO’s WHO Publication Board.